Sarepta Therapeutics Employee Directory
Biotechnology ResearchMassachusetts, United States1001-5000 Employees
Sarepta Therapeutics is a global biotechnology company headquartered in Cambridge, Massachusetts, with between 1,001 and 5,000 employees and annual revenue in the range of $1B to $10B; its website is sarepta.com. The company focuses on developing precision genetic medicines intended to treat rare diseases. In December 2024 Sarepta acquired exclusive global rights from Arrowhead Pharmaceuticals to develop two RNA interference candidates, ARO-DUX4 and ARO-DM1, for muscular dystrophy. In March 2026 Sarepta disclosed early biomarker data for two Arrowhead-licensed RNAi assets, signaling a shift away from its previous gene therapy programs. In February 2026 Jorge Bartolome was appointed chief executive officer and a member of the board, and the company participated in events such as the MDA 2026 conference.